Deerfield Inks First China Biotech Alliance with METIS TECHBIO-P to Advance AI-Driven Protein Therapeutics and In Vivo Immunotherapies

Stock News05-28

On May 28, METIS TECHBIO-P (07666), a global leader in AI-powered drug delivery innovation, announced the formation of a strategic alliance with Deerfield Management, a premier global healthcare investment and innovation platform. This marks Deerfield's first strategic alliance with a Chinese biotechnology company. The collaboration will focus on jointly developing a new generation of in vivo protein therapeutics and immunotherapies, and advancing the global commercialization of the partnered pipeline.

This partnership will integrate METIS TECHBIO-P's differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's deep industrial expertise in translational medicine, clinical development, and global partnerships. The collaboration will center on METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, and its core pipeline. A leading T-cell engager (TCE) project, discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's AiProtein platform, will be a primary focus for advancement. Deerfield will explore licensing and development opportunities for this project to support its progression into IND-enabling studies and clinical stages.

It is reported that METIS TECHBIO-P's self-developed AI nano-delivery platform, NanoForge, employs an innovative paradigm of "dry lab + wet lab + intelligent agents" to power four core solutions: AiLNP, AiRNA, AiProtein, and AiTEM. Deerfield is one of the most industrially influential specialized investment firms in the global life sciences sector, managing over $16 billion in assets. It has invested in more than 200 healthcare companies, with deep involvement in cutting-edge areas such as oncology, autoimmune diseases, RNA therapies, gene editing, and AI-driven drug discovery.

Dr. Lai Caida, Chairman and CEO of METIS TECHBIO-P, stated that Deerfield is one of the most respected healthcare investment and innovation platforms globally. The company is committed to fully accelerating the progress and implementation of this strategic alliance. As a pioneer in exploring precise in vivo immunotherapy, METIS TECHBIO-P will work with Deerfield to build a highly differentiated innovation platform to accelerate the development of breakthrough therapies for patients worldwide.

Dr. Brian Chow, Managing Director at Deerfield, noted that METIS TECHBIO-P continues to drive innovation at the intersection of artificial intelligence, biologics, and in vivo therapeutic engineering. Deerfield looks forward to collaborating with the METIS TECHBIO-P team to jointly advance the development of innovative therapeutic projects powered by its proprietary AI platforms and next-generation delivery technologies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment